Literature DB >> 21910805

Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up.

A Rossi1, C Cantisani, M Scarnò, A Trucchia, M C Fortuna, S Calvieri.   

Abstract

Finasteride 1 mg is indicated for the treatment of men with androgenetic alopecia (AGA). However, more than 5 years efficacy and safety has not been previously reported. To assess the efficacy over 10 years in different age groups of men with AGA. 118 men, between 20 and 61 years, with AGA receiving finasteride (1 mg/day), were enrolled in this uncontrolled study. Efficacy evaluation was assessed with standardized global photographs at T0,T1,T2,T5,T10. Statistical analysis was made using frequency tables and evaluating the chi-square index with its p-value. Better improvements are observed in patients older than 30 years (42.8% aged between 20 and 30 years did not improve also after 10 years) or with higher AGA grades (58.9% for AGA grade IV and 45.4% for AGA grade V had the first improvement just after 1 year). In 21% of cases, the treatment continuation beyond 5 years provided better results. Side effects were referred by 6% of the patients; nevertheless, some of them went on with treatment because of the great results. In our opinion, the result after the first year can help in predicting the effectiveness of the treatment. Its efficacy was not reduced as time goes on; in fact, a big proportion of subjects unchanged after 1 year, improved later on, maintaining a positive trend.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910805     DOI: 10.1111/j.1529-8019.2011.01441.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  14 in total

1.  Finasteride and prostate cancer: a commentary.

Authors:  Channing J Paller; Thomas J Smith
Journal:  Oncologist       Date:  2012-06-20

Review 2.  Androgenetic alopecia: a review.

Authors:  Francesca Lolli; Francesco Pallotti; Alfredo Rossi; Maria C Fortuna; Gemma Caro; Andrea Lenzi; Andrea Sansone; Francesco Lombardo
Journal:  Endocrine       Date:  2017-03-28       Impact factor: 3.633

3.  A new technique for quantitative analysis of hair loss in mice using grayscale analysis.

Authors:  Tulasi Ponnapakkam; Ranjitha Katikaneni; Rohan Gulati; Robert Gensure
Journal:  J Vis Exp       Date:  2015-03-09       Impact factor: 1.355

4.  What's New in Therapy for Male Androgenetic Alopecia?

Authors:  David Saceda-Corralo; Miguel Domínguez-Santas; Sergio Vañó-Galván; Ramon Grimalt
Journal:  Am J Clin Dermatol       Date:  2022-09-28       Impact factor: 6.233

Review 5.  The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.

Authors:  Mohammed A Said; Akanksha Mehta
Journal:  Curr Urol Rep       Date:  2018-06-16       Impact factor: 3.092

Review 6.  Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.

Authors:  Mark S Nestor; Glynis Ablon; Anita Gade; Haowei Han; Daniel L Fischer
Journal:  J Cosmet Dermatol       Date:  2021-11-06       Impact factor: 2.189

7.  Drug Treatment for Androgenetic Alopecia: First Italian Questionnaire Survey on What Dermatologists Think about Finasteride.

Authors:  Elisabetta Sorbellini; Daniela Pinto; Barbara Marzani; Fabio Rinaldi
Journal:  Dermatol Ther (Heidelb)       Date:  2018-03-24

8.  Can we predict prostate size by scoring baldness? The relationship of androgenic alopecia and lower urinary tract symptoms.

Authors:  Nassim Aourag; Johan F Langenhuijsen; Frank d'Ancona; John Heesakkers
Journal:  Cent European J Urol       Date:  2019-03-12

9.  "Cold" X5 Hairlaser™ used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study.

Authors:  Kenneth Blum; David Han; Margaret A Madigan; Raquel Lohmann; Eric R Braverman
Journal:  BMC Res Notes       Date:  2014-02-24

10.  Effectiveness and Safety of Botulinum Toxin Type A in the Treatment of Androgenetic Alopecia.

Authors:  Yaguang Zhou; Shui Yu; Jimin Zhao; Xinyue Feng; Meinan Zhang; Zigang Zhao
Journal:  Biomed Res Int       Date:  2020-08-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.